From metabolic disease, the resolution of insulin resistance by PPARγ and combined PPARα/γ agonists, as well as long-term outcome in patients with type II diabetes, we learned a lot on simultaneous PPARα/γ stimulation. The gene discussed is PPARA; the disease is Insulin resistance.